Related Experiment Video

Updated: Jun 10, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

[Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib]

A Wollenberg1, M Staehler, T Eames

  • 1Klinik und Poliklinik für Dermatologie und Allergologie, Ludwig-Maximilians-Universität, Frauenlobstr. 9-11, 80337, München, Deutschland. wollenberg@lrz.uni-muenchen.de

Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete
|July 16, 2010
PubMed

Insights

Molecular targeted therapies like sorafenib and sunitinib offer new cancer treatments. These drugs cause specific skin side effects that may indicate treatment effectiveness and require management.

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Molecular targeted therapy, including monoclonal antibodies and low molecular weight inhibitors, is crucial for treating malignant tumors.
  • These therapies target dysfunctional regulatory pathways in cancer cells, affecting proliferation, differentiation, and angiogenesis.
  • Multikinase inhibitors like sorafenib and sunitinib present an alternative to conventional chemotherapy with a distinct side effect profile.

Purpose of the Study:

  • To compare the cutaneous side effects of sorafenib and sunitinib.
  • To discuss therapeutic strategies for managing treatment-induced skin reactions.
  • To highlight the potential of skin reactions as biomarkers of antitumor activity.

Main Methods:

  • Review of current literature on sorafenib and sunitinib.
  • Comparative analysis of reported cutaneous side effects.
  • Discussion of treatment options for identified dermatological reactions.

Main Results:

  • Sorafenib and sunitinib induce specific cutaneous side effects.
  • These skin reactions can serve as indicators of the drugs' antitumor efficacy.
  • Management strategies exist for various dermatological reactions associated with these inhibitors.

Conclusions:

  • Cutaneous side effects of sorafenib and sunitinib are common but manageable.
  • Monitoring and treating skin reactions are essential for patient compliance and treatment success.
  • The occurrence of skin toxicity may correlate with positive therapeutic outcomes in cancer treatment.

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...